 This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the clinical and biologic efficacy, as well as the safety of SC doses of AMG 557MEDI5872 in adult subjects with Primary Sjögrens Syndrome. 